PharmAbcine Inc
KOSDAQ:208340
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
PharmAbcine Inc
KOSDAQ:208340
|
KR |
|
P
|
Prestige Biologics Co Ltd
KOSDAQ:334970
|
KR |
|
S
|
Schneider Electric SE
F:SND
|
FR |
|
D
|
Disco Corp
F:D65
|
JP |
Intrinsic Value
There is not enough data to reliably calculate the intrinsic value for PharmAbcine Inc.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What PharmAbcine Does
PharmAbcine Inc. engages in the development of human therapeutic monoclonal antibody (mAb) for the treatment of cancer and inflammatory diseases. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2018-11-21. The firm researching and developing antibody therapeutics to provide patients with the antibodies needed to cure the disease. The Company’s major products include tanibirumab used for cancer treatment, among others. The firm also carries out technology transfer about its pipelines with domestic and overseas pharmaceutical companies.
- Headquarters
- Korea KR
- IPO date
- Nov 21, 2018